Literature DB >> 27083283

Experimental inhibition of porcupine-mediated Wnt O-acylation attenuates kidney fibrosis.

Babita Madan1, Mehul B Patel2, Jiandong Zhang2, Ralph M Bunte3, Nathan P Rudemiller2, Robert Griffiths2, David M Virshup4, Steven D Crowley5.   

Abstract

Activated Wnt signaling is critical in the pathogenesis of renal fibrosis, a final common pathway for most forms of chronic kidney disease. Therapeutic intervention by inhibition of individual Wnts or downstream Wnt/β-catenin signaling has been proposed, but these approaches do not interrupt the functions of all Wnts nor block non-canonical Wnt signaling pathways. Alternatively, an orally bioavailable small molecule, Wnt-C59, blocks the catalytic activity of the Wnt-acyl transferase porcupine, and thereby prevents secretion of all Wnt isoforms. We found that inhibiting porcupine dramatically attenuates kidney fibrosis in the murine unilateral ureteral obstruction model. Wnt-C59 treatment similarly blunts collagen mRNA expression in the obstructed kidney. Consistent with its actions to broadly arrest Wnt signaling, porcupine inhibition reduces expression of Wnt target genes and bolsters nuclear exclusion of β-catenin in the kidney following ureteral obstruction. Importantly, prevention of Wnt secretion by Wnt-C59 blunts expression of inflammatory cytokines in the obstructed kidney that otherwise provoke a positive feedback loop of Wnt expression in collagen-producing fibroblasts and epithelial cells. Thus, therapeutic targeting of porcupine abrogates kidney fibrosis not only by overcoming the redundancy of individual Wnt isoforms but also by preventing upstream cytokine-induced Wnt generation. These findings reveal a novel therapeutic maneuver to protect the kidney from fibrosis by interrupting a pathogenic crosstalk loop between locally generated inflammatory cytokines and the Wnt/β-catenin signaling pathway.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic kidney disease; cytokines; fibrosis

Mesh:

Substances:

Year:  2016        PMID: 27083283      PMCID: PMC4834146          DOI: 10.1016/j.kint.2016.01.017

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  47 in total

Review 1.  Fibrotic disease and the T(H)1/T(H)2 paradigm.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

2.  Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury.

Authors:  Weichun He; Young Sun Kang; Chunsun Dai; Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 10.121

3.  Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis.

Authors:  Sha Hao; Weichun He; Yingjian Li; Hong Ding; Yayi Hou; Jing Nie; Fan Fan Hou; Michael Kahn; Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 10.121

4.  Lineage specification of parietal epithelial cells requires β-catenin/Wnt signaling.

Authors:  Stephan Grouls; Diana Margarita Iglesias; Nicolas Wentzensen; Marcus Johannes Moeller; Maxime Bouchard; Rolf Kemler; Paul Goodyer; Felix Niggli; Hermann-Josef Gröne; Wilhelm Kriz; Robert Koesters
Journal:  J Am Soc Nephrol       Date:  2011-10-21       Impact factor: 10.121

5.  β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis.

Authors:  Christian Beyer; Amelie Schramm; Alfiya Akhmetshina; Clara Dees; Trayana Kireva; Kolja Gelse; Sonali Sonnylal; Benoit de Crombrugghe; Makoto Mark Taketo; Oliver Distler; Georg Schett; Jörg H W Distler
Journal:  Ann Rheum Dis       Date:  2012-02-10       Impact factor: 19.103

6.  A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].

Authors:  Katayoon H Emami; Cu Nguyen; Hong Ma; Dae Hoon Kim; Kwang Won Jeong; Masakatsu Eguchi; Randall T Moon; Jia-Ling Teo; Se Woong Oh; Hak Yeop Kim; Sung Hwan Moon; Jong Ryul Ha; Michael Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

Review 7.  TGF-beta signaling and the fibrotic response.

Authors:  Andrew Leask; David J Abraham
Journal:  FASEB J       Date:  2004-05       Impact factor: 5.191

8.  Blockade of CCR2 ameliorates progressive fibrosis in kidney.

Authors:  Kiyoki Kitagawa; Takashi Wada; Kengo Furuichi; Hiroyuki Hashimoto; Yoshiro Ishiwata; Masahide Asano; Motohiro Takeya; William A Kuziel; Kouji Matsushima; Naofumi Mukaida; Hitoshi Yokoyama
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

9.  Structural basis of Wnt recognition by Frizzled.

Authors:  Claudia Y Janda; Deepa Waghray; Aron M Levin; Christoph Thomas; K Christopher Garcia
Journal:  Science       Date:  2012-05-31       Impact factor: 47.728

10.  Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis.

Authors:  Alfiya Akhmetshina; Katrin Palumbo; Clara Dees; Christina Bergmann; Paulius Venalis; Pawel Zerr; Angelika Horn; Trayana Kireva; Christian Beyer; Jochen Zwerina; Holm Schneider; Anika Sadowski; Marc-Oliver Riener; Ormond A MacDougald; Oliver Distler; Georg Schett; Jörg H W Distler
Journal:  Nat Commun       Date:  2012-03-13       Impact factor: 14.919

View more
  17 in total

1.  Pten deletion in Dmp1-expressing cells does not rescue the osteopenic effects of Wnt/β-catenin suppression.

Authors:  Kyung-Eun Lim; April M Hoggatt; Whitney A Bullock; Daniel J Horan; Hiroki Yokota; Frederick M Pavalko; Alexander G Robling
Journal:  J Cell Physiol       Date:  2020-06-11       Impact factor: 6.384

Review 2.  Modulating the wnt signaling pathway with small molecules.

Authors:  Freddi Huan Tran; Jie J Zheng
Journal:  Protein Sci       Date:  2017-02-11       Impact factor: 6.725

3.  Tubular β-catenin and FoxO3 interactions protect in chronic kidney disease.

Authors:  Stellor Nlandu-Khodo; Yosuke Osaki; Lauren Scarfe; Haichun Yang; Melanie Phillips-Mignemi; Jane Tonello; Kenyi Saito-Diaz; Surekha Neelisetty; Alla Ivanova; Tessa Huffstater; Robert McMahon; M Mark Taketo; Mark deCaestecker; Balakuntalam Kasinath; Raymond C Harris; Ethan Lee; Leslie S Gewin
Journal:  JCI Insight       Date:  2020-05-21

4.  Surprising Enhancement of Fibrosis by Tubule-Specific Deletion of the TGF-β Receptor: A New Twist on an Old Paradigm.

Authors:  David P Basile; Purvi Mehrotra
Journal:  J Am Soc Nephrol       Date:  2017-10-26       Impact factor: 10.121

Review 5.  WNT-β-catenin signalling - a versatile player in kidney injury and repair.

Authors:  Stefan J Schunk; Jürgen Floege; Danilo Fliser; Thimoteus Speer
Journal:  Nat Rev Nephrol       Date:  2020-09-28       Impact factor: 28.314

Review 6.  Wnt/β-Catenin in Acute Kidney Injury and Progression to Chronic Kidney Disease.

Authors:  Tessa Huffstater; W David Merryman; Leslie S Gewin
Journal:  Semin Nephrol       Date:  2020-03       Impact factor: 5.299

Review 7.  WNT Signaling in Cardiac and Vascular Disease.

Authors:  Sébastien Foulquier; Evangelos P Daskalopoulos; Gentian Lluri; Kevin C M Hermans; Arjun Deb; W Matthijs Blankesteijn
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

8.  Opposing actions of renal tubular- and myeloid-derived porcupine in obstruction-induced kidney fibrosis.

Authors:  Xiaohan Lu; Nathan P Rudemiller; Jiafa Ren; Yi Wen; Bo Yang; Robert Griffiths; Jamie R Privratsky; Babita Madan; David M Virshup; Steven D Crowley
Journal:  Kidney Int       Date:  2019-07-31       Impact factor: 10.612

9.  Blockade to pathological remodeling of infarcted heart tissue using a porcupine antagonist.

Authors:  Jesung Moon; Huanyu Zhou; Li-Shu Zhang; Wei Tan; Ying Liu; Shanrong Zhang; Lorraine K Morlock; Xiaoping Bao; Sean P Palecek; Jian Q Feng; Noelle S Williams; James F Amatruda; Eric N Olson; Rhonda Bassel-Duby; Lawrence Lum
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-31       Impact factor: 11.205

10.  Canonical Wnt Signaling Promotes Macrophage Proliferation during Kidney Fibrosis.

Authors:  Ye Feng; Yan Liang; Jiafa Ren; Chunsun Dai
Journal:  Kidney Dis (Basel)       Date:  2018-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.